Hydromer, Inc.
Tel: (908) 722-5000
Video Conferencing IP Address: video.hydromer.com
 PRESS RELEASE:  The following is available for immediate release:     Branchburg, NJ;
October 26, 2006


Hydromer, Inc. Announces a
Non-Leaching Anti-Thrombogenic
Coating for Evaluation


 

Hydromer,Inc., (HYDI.OB – OTC BB; HDO - BSX), a New Jersey biotech company, has developed an anti-thrombogenic polymer coating complex (F202) that minimizes blood coagulation.  The surface bonding capabilities of the F202 polymer, which maintains long-term non-leaching properties, are outstanding on a wide variety of medical materials such as cardiovascular devices and stents, hemodialysis equipment and intravenous catheters.  Hydromer will provide a dossier of data obtained to date to companies interested in investigating the potential applications and the performance of this new polymer, along with test methods used.  Hydromer will be seeking medical device manufacturers who will enter into confidentiality agreements with non-analysis restrictions, submit their device samples for trial coating and provide feedback to Hydromer.  Hydromer expects this evaluation phase to help explore the capabilities of this potentially new ground breaking technology.  The Company expects to file a patent application shortly with the U.S. Patent Office on this new technology.  This release is not to be construed as an offer to sell any products or license any art based on this new technology.

From: Hydromer, Inc.
35 Industrial Parkway
Branchburg, NJ  USA  08876-3424
 Contact:  Martin von Dyck
Executive President
908-722-5000
HYDI.OB OTC Bulletin Board
HDO BSX, Boston Stock Exchange
 http://www.hydromer.com
E-mail for information
Mutual Non-Disclosure Agreement
(please click to load DOC file)

 Technical Data
(please click to load pdf file)

 

This release contains forward-looking statements, including statements regarding Hydromer’s developments in biopolymer molecular entities.  These statements are subject to various risks and uncertainties that could cause actual evaluations of this polymer to differ from those anticipated.  Clients, potential clients and investors are cautioned not to place undue reliance on any forward-looking statements in this release, and are strongly encouraged to review Hydromer’s Annual Report on Form 10-KSB for the year ended June 30, 2006, which is on file with the Securities and Exchange Commission.